Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Iben Kümler"'
Autor:
Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, Maj-Britt Jensen, Saskia Eßer-Naumann, Jeanette Dupont Rønlev, Hanne Melgaard Nielsen, Ann Knoop, Iben Kümler
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background Initial treatment for advanced ER-positive/HER2-negative breast cancer involves a CDK 4/6 inhibitor (CDK 4/6i). Recent overall survival (OS) analyses led the Danish Medical Council to exclude palbociclib as preferred option. This
Externí odkaz:
https://doaj.org/article/d2612f5ad8f047cebfc8ffc4d7d6b96a
Autor:
Alan Celik, Tobias Berg, Magnus Gibson, Maj-Britt Jensen, Iben Kümler, Saskia Eßer-Naumann, Erik H. Jakobsen, Ann Knoop, Dorte Nielsen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: Capecitabine can be used as first-line treatment for advanced breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse. The purpose of the study is to evaluate outcomes of patients with Hum
Externí odkaz:
https://doaj.org/article/9a4a0d4feb1344fe96950898f4981baa
Autor:
Tobias Berg, Maj-Britt Jensen, Maria Rossing, Christian T. Axelsen, Iben Kümler, Lise Søndergaard, Marianne Vogsen, Ann S. Knoop, Bent Ejlertsen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Primary metastatic breast cancer (pMBC) accounts for 5–10% of annual breast cancers with a median survival of 3–4 years, varying among subtypes. In Denmark, the incidence of breast cancer increased until 2010, followed by a stabilisat
Externí odkaz:
https://doaj.org/article/22476371f20f4d8e9fc8ba7ab74c6cb6
Publikováno v:
The Breast Journal, Vol 2024 (2024)
Introduction. Triple-negative breast cancer (TNBC) is a subgroup of breast cancer characterized by the absence of estrogen and the human epidermal 2 receptor and also a lack of targeted therapy options. Chemotherapy has so far been the only approved
Externí odkaz:
https://doaj.org/article/40ecf493b3dd48c18335ffecba2bd888
Autor:
Alan Celik, Tobias Berg, Maj-Britt Jensen, Erik Jakobsen, Hanne Melgaard Nielsen, Iben Kümler, Vesna Glavicic, Jeanette Dupont Jensen, Ann Knoop
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 17 (2023)
Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the opti
Externí odkaz:
https://doaj.org/article/8667cce3158e4750a5ea7c2781852e06
Autor:
Iben Kümler, Eva Balslev, Jan Stenvang, Nils Brünner, Bent Ejlertsen, Erik Hugger Jakobsen, Dorte Lisbet Nielsen
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-5 (2019)
Abstract Background Treatment options in metastatic breast cancer are limited. New therapies preferable with predictive biomarkers are needed. The aim of these trials was to investigate if gene copy number of the topoisomerase 1 gene was predictive o
Externí odkaz:
https://doaj.org/article/d12b0a4ca94f4d26b03f65912e1d1f84
Autor:
Jeppe Thagaard, Elisabeth Specht Stovgaard, Line Grove Vognsen, Søren Hauberg, Anders Dahl, Thomas Ebstrup, Johan Doré, Rikke Egede Vincentz, Rikke Karlin Jepsen, Anne Roslind, Iben Kümler, Dorte Nielsen, Eva Balslev
Publikováno v:
Cancers, Vol 13, Iss 12, p 3050 (2021)
Triple-negative breast cancer (TNBC) is an aggressive and difficult-to-treat cancer type that represents approximately 15% of all breast cancers. Recently, stromal tumor-infiltrating lymphocytes (sTIL) resurfaced as a strong prognostic biomarker for
Externí odkaz:
https://doaj.org/article/30e244141f494b9c91ca7436908cfb23
Autor:
Rasmus Garly, Tobias Berg, Maj-Britt Jensen, Ann Knoop, Lone Volmer, Vesna Glavicic, Humma Khan, Peter Bo Poulsen, Jens Olsen, Iben Kümler
Publikováno v:
Acta Oncologica. 62:290-297
Autor:
Asbjørn Due, Tobias Berg, Maj-Britt Jensen, Sophie Yammeni, Lone Volmer, Anne Sofie Brems-Eskildsen, Klaus Kaae Andersen, Saeeda Rana, Ann Knoop, Iben Kümler
Publikováno v:
Due, A, Berg, T, Jensen, M-B, Yammeni, S, Volmer, L, Brems-Eskildsen, A S, Andersen, K K, Rana, S, Knoop, A & Kümler, I 2023, ' A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients ', Acta Oncologica, vol. 62, no. 2, pp. 126-133 . https://doi.org/10.1080/0284186X.2023.2176257
Background: Current guidelines in HER2-positive metastatic breast cancer (mBC) recommend the combination of trastuzumab and a chemotherapeutic agent for 3rd line or later treatments. This study aims to describe the treatment of HER2-positive mBC in 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6fdae1238291c95b8c578fd876afeb8
Autor:
Elisabeth Specht Stovgaard, Ib Jarle Christensen, Kamille List-jensen, Eva Balslev, Dorte Nielsen, Iben Kümler, Estrid Høgdall, Anne Roslind
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology. 30:62-71
The immune checkpoint molecule lymphocyte activation gene 3 (LAG-3) is currently being investigated as a possible target for immunotherapy in triple-negative breast cancer (TNBC), frequently as an addition to treatment with programmed cell death prot